# Guanosine triphosphate-$^{13}C_{10}$,$^{15}N_5$ tetraammonium

| | |
|---|---|
| **Cat. No.:** | HY-113225S1 |
| **Molecular Formula:** | $^{13}C_{10}H_{28}N_4{}^{15}N_5O_{14}P_3$ |
| **Molecular Weight:** | 606.2 |
| **Target:** | Nucleoside Antimetabolite/Analog; DNA/RNA Synthesis; SARS-CoV; Endogenous Metabolite |
| **Pathway:** | Cell Cycle/DNA Damage; Anti-infection; Metabolic Enzyme/Protease |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |



$NH_3$
$NH_3$
$NH_3$
$NH_3$

## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | Guanosine triphosphate-$^{13}C_{10}$,$^{15}N_5$ (tetraammonium) is the $^{13}C$ and $^{15}N$ labeled Guanosine triphosphate tetraammonium[1]. Guanosine triphosphate is a native nucleotide. The derivatives of GTP may be used as specific inhibitors against COVID-19[2]. |
| **In Vitro** | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

## REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

[2]. Abdo A Elfiky, et al. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020 May 1;248:117477.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA